Lv4
516 积分 2024-11-11 加入
Enhancing population pharmacokinetic modeling efficiency and quality using an integrated workflow
1个月前
已完结
Interventions to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
5个月前
已完结
Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia
5个月前
已完结
Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model
5个月前
已关闭
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial
5个月前
已完结
Leveraging Model-Informed Drug Development to Predict Asciminib Efficacy in Second-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase
5个月前
已完结
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial
5个月前
已完结
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
5个月前
已完结
Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1
6个月前
已关闭
Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1
6个月前
已完结
皖公网安备34019202002308
